Because most immune cells are more sensitive to p53 activation-induced cell death than tumor cells as shown in a previous report [129] and our unpublished observation, targeted p53 activation as an immunotherapy approach will require different dosing and delivery strategies. This evidence concerns the gene TP53 and neoplasm.